Effect of aromatizable and unaromatizable androgen replacement in hypogonadal men on GH responsiveness.
AffiliationDepartment of Endocrinology, Christie Hospital, Wilmslow Road, Withington, Manchester, M20 4BX, UK. email@example.com
MetadataShow full item record
AbstractOBJECTIVES: Although studies have clearly demonstrated that oestrogen replacement affects GH responsiveness by causing relative GH resistance, the effect of androgen replacement is unknown. Circumstantial evidence only suggests that androgen replacement may increase GH sensitivity and/or responsiveness. To examine the impact of androgens on GH responsiveness, hypogonadal men underwent the IGF-1 generation test in the unreplaced state, replaced with testosterone (T) and also replaced with dihydrotestosterone (DHT), its nonaromatizable metabolite. DESIGN AND PATIENTS: Twelve hypogonadal men with a normal GH axis were recruited. Each subject in random order had 4 weeks off T (NoRx), 4 weeks on T gel (TG) and 4 weeks on DHT gel (DHTG) applied daily, with 1 week washout between each preparation. An IGF-1 generation test using a subcutaneous injection of 7 mg of GH was performed at the end of each of these 4-week phases. MEASUREMENTS: Serum GHBP, total and free IGF-1, IGFBP-3 and acid-labile subunit (ALS) levels were measured at baseline and 24 h (peak) after GH administration. RESULTS: Despite a decrease in GHBP during the TG and DHTG phases, there were no observed differences in baseline, peak or increment (peak - baseline) total or free IGF-1 between the NoRx, TG or DHTG phases. CONCLUSIONS: There is no evidence of fluctuation in GH responsiveness in hypogonadal men, untreated or replaced with T or DHT alone. This implies that the increased level of oestradiol as a consequence of T replacement in hypogonadal men does not impact significantly on GH responsiveness, nor is there evidence of an androgen effect with elevated DHT levels as a consequence of either T or DHT replacement.
CitationEffect of aromatizable and unaromatizable androgen replacement in hypogonadal men on GH responsiveness. 2009, 70 (1):109-15 Clin. Endocrinol. (Oxf)
- The growth hormone (GH)-insulin-like growth factor axis during testosterone replacement therapy in GH-treated hypopituitary males.
- Authors: Fisker S, Nørrelund H, Juul A, Skakkebaek NE, Christiansen JS, Jørgensen JO
- Issue date: 2001 Apr
- Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting.
- Authors: Grinspoon S, Corcoran C, Lee K, Burrows B, Hubbard J, Katznelson L, Walsh M, Guccione A, Cannan J, Heller H, Basgoz N, Klibanski A
- Issue date: 1996 Nov
- Recombinant human growth hormone and recombinant human insulin-like growth factor I diminish the catabolic effects of hypogonadism in man: metabolic and molecular effects.
- Authors: Hayes VY, Urban RJ, Jiang J, Marcell TJ, Helgeson K, Mauras N
- Issue date: 2001 May
- Effects of androgen administration on the growth hormone-insulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting.
- Authors: Grinspoon S, Corcoran C, Stanley T, Katznelson L, Klibanski A
- Issue date: 1998 Dec
- Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I.
- Authors: Christiansen JJ, Fisker S, Gravholt CH, Bennett P, Svenstrup B, Andersen M, Feldt-Rasmussen U, Christiansen JS, Jørgensen JO
- Issue date: 2005 May